

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



国药集团  
SINOPHARM

# 國藥控股股份有限公司 SINOPHARM GROUP CO. LTD.\*

*(A joint stock limited company incorporated in the People's Republic of China with limited liability and carrying on business in Hong Kong as 國控股份有限公司)*

**(Stock Code: 01099)**

## ANNOUNCEMENT

### IN RELATION TO WITHDRAWAL OF A RESOLUTION AT THE AGM

References are made to the circular (the “**Circular**”) and the notice (the “**Notice**”) of the annual general meeting for the year 2023 (the “**AGM**”), both dated 24 May 2024, of Sinopharm Group Co. Ltd. (the “**Company**”) and the proxy form for the AGM (the “**Proxy Form**”), in relation to, among other things, the ordinary resolution numbered 7 regarding the proposal on the appointment of PricewaterhouseCoopers and PricewaterhouseCoopers Zhong Tian LLP (collectively, “**PwC**”) as the international auditor and the domestic auditor of the Company (the “**Resolution**”). Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as those defined in the Circular.

Since the relevant matters of recent media rumors in relation to the Company’s auditors require further verification, based on the principle of prudence, the Board has decided to withdraw the Resolution from the AGM. The Board will consider and propose for the Shareholders’ consideration of an appropriate firm to be appointed as the domestic and international auditors of the Company for the year 2024 as soon as practicable. The Company will issue announcement(s) and circular(s) in due course and convene an extraordinary general meeting to consider the relevant proposal. PwC has confirmed to the Company that there are no matters that need to be brought to the attention of the Shareholders of the Company. The Company has confirmed that there is no disagreement or unresolved matters between the Company and PwC and there are no other matters that need to be brought to the attention of the Shareholders of the Company.

*\* The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance under its Chinese name and the English name “Sinopharm Group Co. Ltd.”.*

Save for the withdrawal of the Resolution, all other information and contents as set out in the Circular, the Notice and the Proxy Form remain unchanged. The Proxy Form lodged by the Shareholders will remain valid except that no poll will be conducted or counted for the Resolution. Shareholders are reminded to read the Notice (including notes therein) for details of other resolutions which remain scheduled for consideration and approval at the AGM, eligibility for attending the AGM and appointment of proxy and other relevant matters.

By Order of the Board  
**Sinopharm Group Co. Ltd.**  
**Yu Qingming**  
*Chairman*

Shanghai, the PRC  
7 June 2024

*As at the date of this announcement, the executive directors of the Company are Mr. Yu Qingming and Mr. Liu Yong; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Hu Jianwei, Mr. Deng Jindong, Mr. Wang Kan, Mr. Wang Peng, Mr. Wen Deyong, Mr. Li Dongjiu and Ms. Feng Rongli; and the independent non-executive directors of the Company are Mr. Chen Fangruo, Mr. Li Peiyu, Mr. Wu Tak Lung, Mr. Yu Weifeng and Mr. Shi Shenghao.*